Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
APPY > SEC Filings for APPY > Form 8-K on 16-Nov-2012All Recent SEC Filings

Show all filings for ASPENBIO PHARMA, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for ASPENBIO PHARMA, INC.


16-Nov-2012

Entry into a Material Definitive Agreement, Financial Statements and Exhibi


Item 1.01 Entry into a Material Definitive Agreement.

On November 14, 2012 and November 15, 2012, AspenBio Pharma, Inc. (the "Company") entered into two (2) underwriting agreements (collectively, the "Underwriting Agreements") with Aegis Capital Corp. (the "Representative"), as representative of the several underwriters (the Representative and such other underwriters, collectively, the "Underwriters"), for firm commitment underwritten public offerings of an aggregate 1,946,000 shares (the "Shares") of the Company's common stock, no par value (the "Common Stock"). All of the Shares are being sold by the Company. The offering price to the public is $2.10 per share, and the Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreements at a price of $1.95 per share. After underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds from the offering of approximately $3.7 million. Under the terms of the Underwriting Agreements, the Company has granted the Underwriters an option, exercisable for 45 days, to purchase up to an additional 291,900 shares of Common Stock to cover overallotments, if any, at the same price per share as the Shares.

The Shares will be issued pursuant to a registration statement on Form S-3 of the Company filed with the Securities and Exchange Commission, which became effective on July 27, 2011 (File No. 333-174213). The closing of the offering is expected to take place on November 20, 2012, subject to the satisfaction of customary closing conditions.

The Underwriting Agreements contain customary representations, warranties, and covenants by the Company. They also provide for customary indemnification by each of the Company and the Underwriters for losses or damages arising out of or in connection with the sale of the Common Stock. In addition, pursuant to the terms of the Underwriting Agreements, each of the Company's officers and directors have entered into agreements with the Underwriters not to sell, transfer or otherwise dispose of securities of the Company during the 90-day period following November 15, 2012.

Copies of the Underwriting Agreements are attached to this Current Report on Form 8-K as Exhibits 1.1 and 1.2 and are incorporated herein by reference. The foregoing description of the material terms of the Underwriting Agreements does not purport to be complete and is qualified in its entirety by reference to the exhibits attached hereto.

On November 14, 2012, the Company issued a press release announcing the pricing of the offering of shares of its Common Stock, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

1.1 Underwriting Agreement by and between AspenBio Pharma, Inc. and Aegis Capital Corp. dated November 14, 2012.

1.2 Underwriting Agreement by and between AspenBio Pharma, Inc. and Aegis Capital Corp. dated November 15, 2012.

5.1 Opinion of Ballard Spahr LLP.

99.1 Press Release of AspenBio Pharma, Inc. titled "AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock," issued November 14, 2012.


  Add APPY to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for APPY - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.